Argatroban anticoagulation in intensive care patients: Effects of heart failure and multiple organ system failure

Journal of Intensive Care Medicine

Volumn 23, Issue 5, 2008, Pages 313-320

  Begelman, Susan M ^a,c   Baghdasarian, Sarkis B ^a   Singh, Inder M ^a   Militello, Michael A ^a   Hursting, Marcie J ^b   Bartholomew, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Clinical Science Consulting   (United States)

^c GENENTECH INC   (United States)

Author keywords

Argatroban; Heart failure; Heparin induced thrombocytopenia; Multiple organ system failure

Indexed keywords

ARGATROBAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; AMPUTATION; ANAMNESIS; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; FEMALE; FOOT DISEASE; HEART FAILURE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; ISCHEMIA; LABORATORY DIAGNOSIS; LABORATORY TEST; MALE; MEDICAL RECORD REVIEW; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STROKE; SUPERFICIAL VEIN THROMBOSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HEPARIN; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 41149174536     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066608321246     Document Type: Article

References (30)

1. Jang IK, Hursting MJ When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005 ; 111: 2671-2683.
2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest. 2004 ; 126: 311S - 337S.
3. Verma AK, Levine M., Shalansky SJ, Carter CJ, Kelton JG Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003 ; 23: 745-753.
4. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005 ; 20: 348-353.
5. Strauss R., Wehler M., Mehler K., Kreutzer D., Koebnick C., Hahn EG Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002 ; 30: 1765-1771.
6. Francis JL, Palmer GJ, Moroose R., Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003 ; 75: 17-22.
7. Greinacher A., Eichler P., Lubenow N., Kwasny H., Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2002 ; 96: 846-851.
8. Hirsh J., Heddle N., Kelton JG Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004 ; 164: 361-369.
9. DeEugenio, DL, Ruggiero NJ, Thomson LJ, Menajovsky LB, Herman JH Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature. Pharmacotherapy. 2005 ; 25: 615-619.
10. Keeling D., Davidson S., Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006 ; 133: 259-269.
11. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline ; 2005.
12. Lewis BE, Matthai WH Jr, Cohen M., Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent. 2002 ; 57: 177-184.
13. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 ; 103: 1838-1843.
14. Lewis BE, Wallis DE, Leya F., Hursting MJ, Kelton JG Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003 ; 163: 1849-1856.
15. Matthai WH, Lewis BE, Hursting MJ, Lewis BE, Kelton JG Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res. 2005 ; 116: 121-126.
16. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006 ; 129: 1407-1416.
17. Kodityal S., Nguyen PH, Kodityal A., Sherer J., Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med. 2006 ; 21: 86-92.
18. Williamson DR, Boulanger I., Tardif M., Albert M., Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy. 2004 ; 24: 409-414.
19. Reichert MG, MacGregor DA, Kincaid EH, Dolinsky SY Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother. 2003 ; 37: 652-654.
20. Koster A., Buz S., Hetzer R., Kuppe H., Breddin K., Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg. 2006 ; 132: 699-700.
21. Vincent JL, de Medonca A., Cantraine F., Moreno R., Takala J., Suter PM Use of the SOA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998 ; 26: 1793-1800.
22. Warkentin TE Heparin-induced thrombocytopenia. Diagnosis and management. Circulation. 2004 ; 110: e454 - e458.
23. Lo GK, Juhl D., Warkentin TE, Sigouin CS, Eichler P., Greinacher A. Evaluation of pretest clinical score (4 Ts) for the diagnosis of heparin-induced thrombocytopenia in 2 clinical settings. J Thromb Haemost. 2006 ; 4: 759-765.
24. Swan SK, Hursting MJ The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000 ; 20: 318-329.
25. Kubo SH, Walter BA, John DH, Clark M., Cody RJ Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med. 1987 ; 147: 1227-1230.
26. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest. 2006 ; 129: 1167-1175.
27. Murray PT, Reddy BV, Grossman EJ, et al. A prospective study of 3 argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004 ; 66: 2446-2453.
28. Tang IY, Cox DS, Patel K., et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005 ; 39: 231-236.
29. Arpino PA, Hallisey RK Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother. 2004 ; 38: 25-29.
30. Guzzi LM, Hursting MJ, McCollum DA Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2006 ; 22: 169-176.